MDACC Study No:2013-0564 ( NCT No: NCT01925612)
Title:A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) as front-line therapy in patients with diffuse large B-cell lymphoma (DLBCL)
Principal Investigator:Luis E. Fayad
Treatment Agent:Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if 2 different doses of
brentuximab vedotin, when combined with standard chemotherapy, can help to
control DLBCL. The safety of this drug combination will also be studied.

The standard chemotherapy used in this study is called RCHOP, which is a
combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and

Brentuximab vedotin is designed to attach to a protein called CD30, which may
cause these cells to die. CD30 is found on some normal cells in the body’s
immune system and on some types of cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Brentuximab Vedotin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Luis E. Fayad
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults